In another phase I trial, combination therapy with compound 3 and the HDAC inhibitor abexinostat demonstrated that HDAC inhibition could promote response and reverse resistance to compound 3 in patients with renal cell carcinoma and other solid tumor malignancies [59]. This evidence concerns the gene HDAC9 and hereditary clear cell renal cell carcinoma.